Indeed, the deleterious effect of TET2 knockdown can be reversed by treatment with the NLRP3 inhibitor MCC950, indicating the pivotal role of IL-1β/NLRP3 inflammasome in TET2 atherosclerosis-related signaling (Fuster et al., 2017). This evidence concerns the gene NLRP3 and atherosclerosis.